- Home
- APLT vs KUKE Comparison
APLT vs KUKE Comparison
Compare APLT & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- KUKE
- Stock Information
- Founded
- APLT 2016
- KUKE 2002
- Country
- APLT United States
- KUKE China
- Employees
- APLT N/A
- KUKE N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- APLT Health Care
- KUKE Real Estate
- Exchange
- APLT Nasdaq
- KUKE Nasdaq
- Market Cap
- APLT 37.5M
- KUKE N/A
- IPO Year
- APLT 2019
- KUKE 2021
- Fundamental
- Price
- APLT $0.41
- KUKE $4.51
- Analyst Decision
- APLT Buy
- KUKE
- Analyst Count
- APLT 7
- KUKE 0
- Target Price
- APLT $6.10
- KUKE N/A
- AVG Volume (30 Days)
- APLT 1.9M
- KUKE 11.7K
- Earning Date
- APLT 05-20-2025
- KUKE 05-20-2025
- Dividend Yield
- APLT N/A
- KUKE N/A
- EPS Growth
- APLT N/A
- KUKE N/A
- EPS
- APLT N/A
- KUKE N/A
- Revenue
- APLT $455,000.00
- KUKE $14,784,158.00
- Revenue This Year
- APLT $1,768.13
- KUKE N/A
- Revenue Next Year
- APLT $361.28
- KUKE N/A
- P/E Ratio
- APLT N/A
- KUKE N/A
- Revenue Growth
- APLT N/A
- KUKE 10.48
- 52 Week Low
- APLT $0.30
- KUKE $0.15
- 52 Week High
- APLT $10.62
- KUKE $4.58
- Technical
- Relative Strength Index (RSI)
- APLT 48.67
- KUKE 71.80
- Support Level
- APLT $0.39
- KUKE $4.05
- Resistance Level
- APLT $0.49
- KUKE $4.55
- Average True Range (ATR)
- APLT 0.04
- KUKE 0.29
- MACD
- APLT 0.01
- KUKE -0.06
- Stochastic Oscillator
- APLT 55.40
- KUKE 90.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.